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effect of clonidine coadministration and sex-related differences
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Background/aim: Treating animals repeatedly with intermittent and increasing morphine doses has been suggested to allow some
withdrawal during each dosing interval, which causes repeated stress. The present study aimed to test this hypothesis and assess sexrelated differences in withdrawal signs and their suppression by clonidine.
Materials and methods: Male and female rats and mice were administered with increasing doses of morphine twice daily at different
dosing intervals. Rats were given clonidine in drinking water (5 µg/mL). Spontaneous and naloxone-precipitated withdrawal signs and
novelty-induced grooming were evaluated.
Results: Male rats and male and female rats displayed manifestations of morphine withdrawal at the end of 14-h and 24-h dosing
intervals, respectively. Clonidine attenuated the severity of the withdrawal signs. Male but not female mice displayed withdrawal signs
at the end of 12-h and 17-h dosing intervals. Female mice exhibited less pronounced naloxone-precipitated withdrawal syndrome.
Grooming did not reflect a “stress-like state” in morphine-treated animals.
Conclusion: These findings indicate intermittent morphine treatment-induced spontaneous withdrawal in rats and mice and sexrelated differences in spontaneous and naloxone-precipitated withdrawal signs in mice. Since the treatment protocol closely parallels
the drug use pattern in opioid addicts, further experiments are needed to clarify the stress associated with the treatment and the efficacy
of sedatives.
Key words: Morphine, intermittent treatment, clonidine, spontaneous withdrawal, grooming, sex, dependence

1. Introduction
The effectiveness of morphine and other opiates in the
management of pain is limited by the development of
tolerance and physical dependence with prolonged or
repeated administrations (1). Following long-duration
opiate intake, abrupt drug withdrawal results in multiple
aversive somatic signs and behavioral changes that may
play a key role in maintaining continued drug use (2). The
alpha 2-adrenergic agonist clonidine alleviates most of the
somatic signs of opiate withdrawal syndrome (3).
Experimental studies in animals have shown that longterm exposure to morphine induces physical dependence
manifested by somatic withdrawal symptoms when
the drug is withheld or soon after the administration of
naloxone or other opiate antagonists. Several studies have
demonstrated sex-related differences in the expression of
withdrawal signs (4–8). Many techniques were developed
to render rodents rapidly dependent on morphine. These
* Correspondence: engnur@istanbul.edu.tr
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include constant treatments provided by infusions (9,10) or
implanted slow-release pellets (11,12) and daily injections
of constant or escalating doses (6,8,13–16). Treating
animals repeatedly with intermittent and increasing
morphine doses is suggested to mimic opiate use patterns in
humans (8). In contrast to constant treatments, injections
of morphine in escalating doses at 12-h intervals result
in elevated basal plasma adrenocorticotropic hormone
and corticosterone concentrations. A “stress-like” state
is suggested to occur in response to repeated cycles of
partial withdrawal associated with intermittent treatment
regimen (17,18). It is well known that stress contributes
to the development and course of addictive behavior in
humans (19). Stressors in animals also reinstate heroin
self-administration (20) or increase morphine intake (21).
The aims of the present study were to assess the “stresslike” state and spontaneous withdrawal associated with
intermittent morphine treatment in male and female
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rats and mice, the sex-related differences in spontaneous
as well as naloxone-precipitated morphine withdrawal
symptoms, and the effect of clonidine on withdrawal
signs associated with intermittent treatment. Noveltyinduced grooming behavior was used to evaluate the stress
response. Clonidine was given during dose intervals.
Because repeated injections may cause additional stress,
the drug was added to the drinking water of the animals
(22–24).
2. Materials and methods
2.1. Animals
Inbred male (280–380 g) and female (220–255 g) Wistar
albino rats and male and female (25–30 g) BALB/c mice
were obtained from the Animal Care Unit of the Institute
for Experimental Medicine of İstanbul University. Sixtythree rats and 60 mice were used in the study. The animals
were housed 5 (rats) and 6 or 7 (mice) per cage under a
regular light/dark schedule (lights on at 0700 hours) for at
least 1 week prior to experimentation and were allowed free
access to both food and water. All studies were approved
by the Local Ethics Committee on Animal Experiments
(İstanbul University, 08/2009, 66-67/2010).
2.2. Drugs
Morphine (Verenigde Pharmaceutische Fabriken BV,
Holland) and naloxone hydrochloride (Sigma, St.
Louis, MO, USA) were dissolved in saline. Clonidine
hydrochloride (Sigma) was added to tap water. Rats were
injected with morphine and naloxone subcutaneously
(s.c.) in a volume of 1 mL/kg body weight. Mice were
injected with morphine intraperitoneally (i.p.) and with
naloxone s.c. in a volume of 10 and 1 mL/kg body weight,
respectively. Drug solutions were prepared fresh every day.
Clonidine dose was chosen according to our previous study
(24). Naloxone dose was chosen according to the studies
referred to for the induction of morphine dependence in
rats and mice, as indicated below.
2.3. Induction of morphine dependence in male and
female rats and mice
In Experiment I, development of spontaneous withdrawal
associated with intermittent morphine treatment and
effect of clonidine administration on spontaneous and
naloxone-precipitated withdrawal signs were assessed
in rats. The intermittent treatment regimen employed
was based on studies by Caille et al. (25) and Houshyar
et al. (17,18). In this regimen, morphine was given twice
daily at 12-h intervals with increasing doses each day. A
modification was made in the injection schedule that
provided interdose intervals of 10 and 14 h. Because
extension of the time interval between doses may induce
more withdrawal, clonidine was given during the 14-h time
period. Male rats were randomly divided into 4 groups

(n = 10 animals): control (saline; tap water), clonidine
(saline; tap water with clonidine), morphine (morphine;
tap water), and morphine + clonidine (morphine; tap
water with clonidine). For 4 days, the animals received
saline twice a day (at 0830 and 1830 hours) or increasing
doses of morphine as follows (in mg/kg of body weight):
day 1 (10, 10), day 2 (20, 20), day 3 (30, 30), and day 4 (40,
40). The final saline and morphine (40 mg/kg) injections
were delivered at 0830 hours on day 5. Throughout the
experiment, control and morphine groups received plain
tap water. Clonidine and morphine + clonidine groups
received tap water containing clonidine (5 µg/mL) from
1830 to 0830 hours (14-h withdrawal) and plain tap water
from 0830 to 1830 hours. Water consumption during
14-h dosing intervals was measured every morning in
all groups. Mean daily water consumption per rat was
calculated by dividing the total daily water consumption
by the number of animals present in the cage. Two animals
died (one in the morphine group and one in the morphine
+ clonidine group) during the course of the experiments.
In Experiment II, development of spontaneous
withdrawal associated to intermittent morphine treatment
and sex-related differences in spontaneous and naloxoneprecipitated withdrawal signs were assessed in rats. The
intermittent treatment regimen employed in the present
study was based on a study by Streel et al. (26). Male and
female rats were randomly divided into control (saline)
and morphine groups (n = 5–9 animals). For 3 days, the
animals received saline twice a day (at 1000 and 1600
hours) or increasing doses of morphine as follows (in mg/
kg of body weight): day 1 (10, 20), day 2 (30, 40), and day
3 (50, 50). During the next 3 days, the rats received saline
or a regular dose of morphine once a day (at 1200 hours).
The doses were as follows (in mg/kg of body weight): day 4
(50), day 5 (50), and day 6 (50).
Intermittent morphine treatment is widely used in mice
for the induction of dependence (8,14,16). Therefore, in
Experiment III, development of spontaneous withdrawal
associated with intermittent morphine treatment and
sex-related differences in spontaneous and naloxoneprecipitated withdrawal signs were also assessed in mice.
The intermittent treatment regimens employed were
based on studies conducted by Papaleo and Contarino (8)
and Li et al. (14). Male and female mice were randomly
divided into control (saline) and morphine groups (n =
6–10 animals). In the first regimen (M-10/50), the animals
received saline twice a day for 5 days (at 0800 and 2000
hours) or increasing doses of morphine as follows (in mg/
kg of body weight): day 1 (10, 10), day 2 (20, 20), day 3 (30,
30), day 4 (40, 40), and day 5 (50, 50). The final saline and
morphine (50 mg/kg) injections were delivered at 0800
hours on day 6. In the second regimen (M-20/100), the
animals received saline twice a day for 5 days (at 0900 and
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1600 hours) or increasing doses of morphine as follows (in
mg/kg of body weight): day 1 (20, 20), day 2 (40, 40), day
3 (60, 60), day 4 (80, 80), and day 5 (100, 100). The final
saline or morphine (100 mg/kg) injections were delivered
at 0900 hours on day 6.
2.4. Measurement of stress response and spontaneous
withdrawal signs
Animals were placed individually into wire mesh
observation cages (width and length 30 cm, height 25
cm) just before the final injections (at the end of a 14-h
dosing interval in Experiment I, 24-h dosing interval
in Experiment II, and 12- and 17-h dosing intervals in
Experiment III). Following a 1-min habituation period, rats
were observed for 5 min and mice for 10 min for grooming
behavior and spontaneous withdrawal signs. Grooming
activities were considered as scratching of body and face
and licking of body fur, tail, limbs, and genital area. Total
time spent grooming was also measured in rats. Grooming
frequency was recorded in mice by giving a score for the
presence of grooming behavior every 15 s (27). Teeth
chattering, ptosis, urination, cheek tremors, freezing,
eye blinking, sniffing, and wet dog shakes were assessed
as somatic signs of spontaneous morphine withdrawal
in rats. Ptosis, urination, cheek tremors, freezing, eye
blinking, and diarrhea were assessed as somatic signs of
spontaneous morphine withdrawal in mice. One point was
attributed for each observed sign and a global withdrawal
score was calculated for each animal by summing up all
the checked signs (28).
2.5. Measurement of naloxone-precipitated withdrawal
signs
Animals were treated with 1 mg/kg naloxone 2 h after
the final injections and were then placed individually
into observation cages. The occurrence of escape jumps
(jumping frequency) was recorded for 15 min. Animals
were weighed before and after the naloxone challenge to
determine body weight loss. On test days, the animals
were acclimatized to the experimental room 1 h prior to
experimentation. Experiments took place under quiet
conditions and in dim light. The observation cages were
cleaned thoroughly with wet and dry cloths between
each test. A trained observer who was blinded to the
treatment given to each group carried out all behavioral
measurements.
2.6. Statistical analysis
All data analyses were performed using SPSS 21.0. Oneway analysis of variance (ANOVA) was used to compare
global withdrawal score, duration and frequency of
grooming, body weight loss, and jumping frequency data
collected from the animals. The Bonferroni test was used
for group comparisons. Significance was accepted at the P
< 0.05 level. For the estimation of the statistical power of
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the study, post hoc power analysis was performed using
G*Power 3.1.9.2 Statistical Analysis. Power analysis for
prediction of water intake, grooming duration, global
withdrawal score, weight loss, and jumping in Experiment
I and II, and for global withdrawal score and jumping
in the M-10/50 group and grooming frequency, global
withdrawal score, and jumping in the M/20-100 group in
Experiment III revealed a statistical power of more than
80% for our sample size, with an α error of 0.05. Power
of grooming frequency was 50% in the M-10/50 group.
Power of body weight loss was 8% and 13% in the M-10/50
and M-20/100 groups, respectively.
3. Results
In Experiment I, average water consumption for each rat
during the 14-h time period was calculated as 22.4 ± 0.86,
13.1 ± 1.85, 10.8 ± 2.74, and 6.5 ± 1.35 mL in the control,
clonidine, morphine, and morphine + clonidine groups,
respectively. One-way ANOVA revealed significant
differences among the groups in terms of water intake
[F (3,34) = 12.704; P < 0.001]. Clonidine, morphine,
and morphine + clonidine groups had lower water
consumption compared to the control group (P < 0.001).
Approximate average dose of clonidine consumed daily
by each rat was 65.5 ± 8.59 and 26.6 ± 4.77 µg/mL in the
clonidine and morphine + clonidine groups, respectively.
Novelty-induced grooming behavior and spontaneous and
naloxone-precipitated withdrawal in rats determined on
day 5 are shown in Figure 1. At the end of the 14-h dosing
interval, one-way ANOVA revealed significant differences
among the groups in terms of grooming duration [F(3,34)
= 6.023; P < 0.01] and withdrawal signs [F(3,34) = 8.282;
P < 0.001]. Total time spent on grooming was less in the
morphine (P < 0.01) and morphine + clonidine (P < 0.05)
groups compared to the control group. Animals in the
morphine (P < 0.001) and morphine + clonidine (P < 0.01)
groups showed marked global withdrawal scores compared
to the control animals. Withdrawal was less severe in the
morphine + clonidine group compared to the morphine
group (P < 0.05). One-way ANOVA revealed significant
differences between the groups in body weight loss [F(3,34)
= 3.785; P < 0.05] and jumping frequency [F(3,34) = 9.362;
P < 0.001] after naloxone administration. Animals in the
morphine (P < 0.05; P < 0.001) and morphine + clonidine
(P < 0.05; P < 0.01) groups exhibited marked weight loss
and number of jumps compared to the control animals.
In Experiment II, novelty-induced grooming behavior
and spontaneous and naloxone-precipitated withdrawal
signs in male and female rats determined on day 6 are
shown in Figure 2. At the end of the 24-h dosing interval,
one-way ANOVA revealed significant differences between
the groups in terms of withdrawal signs [F(3,21) = 19.083;
P < 0.001], although not in grooming duration [F(3,21) =
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Figure 1. Spontaneous withdrawal and grooming activity observed at the end of the 14-h dosing interval, and naloxone-precipitated
weight loss and jumping observed 2 h after the final injections in intermittent morphine administration in rats. Animals were injected
s.c. with saline or morphine (10–40 mg/kg) for 5 days (twice daily on days 1, 2, 3, and 4 and once daily on the morning of day 5).
Clonidine (5 µg/mL) was given in drinking water during the 14-h time period. Withdrawal signs and calculation of global withdrawal
score were described in the text. Results are presented as means ± SEM (n = 9–10 rats for each group). Number of jumps in the control
and clonidine groups are 0.0 ± 0.00.
*: P < 0.05, **: P < 0.01, ***: P < 0.001 difference from the control group; #: P < 0.05 difference from the morphine group.

2.183; P > 0.05]. Both male and female rats treated with
morphine showed marked global withdrawal scores
compared to their relative control groups (P < 0.01).
One-way ANOVA also revealed significant differences
between the groups in body weight loss [F(3,21) = 9.017;

P < 0.001] and jumping frequency [F(3,21) = 10.795; P <
0.001]. Male (P < 0.01; P < 0.05) and female (P < 0.05)
rats in the morphine groups exhibited marked weight loss
and number of jumps compared to the same-sex control
animals.
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Figure 2. Spontaneous withdrawal and grooming activity observed at the end of 24-h dosing interval, and naloxone-precipitated weight
loss and jumping observed 2 h after the final injections in intermittent morphine administration in male and female rats. Animals were
treated s.c. with saline or increasing doses of morphine (10–50 mg/kg) for 6 days (twice daily on days 1, 2, and 3 and once daily on days
4, 5, and 6). Withdrawal signs and calculation of global withdrawal score were described in the text. Results are presented as means ±
SEM (n = 5–9 rats for each group). Number of jumps in male and female control animals are 0.0 ± 0.00.
*: P < 0.05, **: P < 0.01 difference from the same-sex control groups.

In Experiment III, novelty-induced grooming
behavior and spontaneous and naloxone-precipitated
withdrawal in male and female mice determined on day
6 are shown in Figure 3. At the end of the 12-h dosing
interval in the M-10/50 dose regimen, one-way ANOVA
revealed significant differences between the groups in the
global withdrawal score [F(3,28) = 7.377; P < 0.001] and
grooming frequency [F(3,28) = 3.366; P < 0.05]. Male
mice but not female mice treated with morphine showed a
marked global withdrawal score compared with the samesex control animals (P < 0.01). Post hoc analysis did not
reveal significant differences between morphine-treated
and control animals for the grooming activity. One-way
ANOVA also revealed significant differences between the
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groups in the body weight loss [F(3,28) = 3.055; P < 0.05]
and jumping frequency [F(3,28) = 7.275; P < 0.001] after
naloxone administration. Male animals but not females
treated with morphine had higher body weight loss (P
< 0.05) and number of jumps (P < 0.01) compared to
same-sex control animals. At the end of the 17-h dosing
interval in the M-20/100 dose regimen, one-way ANOVA
revealed significant differences among the groups both in
global withdrawal score [F(3,24) = 9.779; P < 0.001] and
grooming frequency [F(3,24) = 5.979; P < 0.01]. Male
mice but not female mice treated with morphine showed
higher global withdrawal score (P < 0.001), and both
male and female morphine-treated mice showed a lower
number of grooming actions (P < 0.05) compared to their
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Figure 3. Spontaneous withdrawal and grooming activity observed at the end of 12-h (M-10/50) or 17-h (M-20/100) dosing intervals,
and naloxone-precipitated weight loss and jumping observed 2 h after the final injections in intermittent morphine administration in
male and female mice. Animals were treated s.c. with saline or increasing doses of morphine (10–50 or 20–100 mg/kg) for 6 days (twice
daily on days 1, 2, and 3, and once daily on days 4, 5, and 6). Withdrawal signs and calculation of global withdrawal score were described
in the text. Results are presented as means ± SEM (n = 6–10 mice for each group). Number of jumps in M-10/50 and M-20/100 male
and female control animals is 0.0 ± 0.00.
*: P < 0.05, **: P < 0.01, ***: P < 0.001 difference from the same-sex control groups.

relative control groups. One-way ANOVA also revealed
significant differences between the groups in body weight
loss [F(3,24) = 6.944; P < 0.01] and jumping frequency
[F(3,24) = 8.830; P < 0.001] after naloxone administration.
Morphine-treated male mice had higher body weight loss
and number of jumps (P < 0.01), and female mice had
higher number of jumps (P < 0.05) compared to the samesex control animals.
4. Discussion
This study was designed for the following purposes: first,
to investigate the hypothesis that induction of morphine

dependence by intermittent injections may induce stress
and allow some withdrawal during treatment; and, second,
to evaluate the sex-related differences in withdrawal
symptoms. Our results showed that novelty-induced
grooming behavior could not imply a “stress-like state” in
rats and mice treated intermittently with increasing doses
of morphine. The treatment protocols, however, produced
marked manifestations of spontaneous withdrawal at the
end of the dosing interval. Administration of clonidine
during dose intervals attenuated the withdrawal signs.
The expression of spontaneous and naloxone-precipitated
withdrawal syndrome, on the other hand, did not
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significantly differ in male and female rats, but appeared
somewhat less pronounced in female mice compared to
males.
The degree and severity of physical dependence on
opioids is influenced by dose, frequency (dosing interval),
and duration of drug administration (9,29). It has been
suggested that frequency is the most important factor
(29). In studies with daily morphine injections, animals
receive each dose at equal (6,18,25,30) or unequal dosing
intervals (6,13,15,31). In the present study, animals were
given intermittent morphine injections with different
interdose intervals for a better assessment of spontaneous
withdrawal associated to the treatment regimen.
Following long-term morphine administration,
abrupt withdrawal elicits spontaneous withdrawal in rats
as expressed by wet dog shakes, jumping, paw tremor,
diarrhea, ptosis, teeth chattering, piloerection, eye blinking,
salivation, grooming, body weight loss, and reduction
in food consumption and water intake (9,15,25,28,32).
Somatic signs of spontaneous morphine withdrawal in
mice are diarrhea, body weight loss, jumping, wet dog
shake, ptosis, paw tremor, and head shaking (8,14,30). In
the present study, spontaneous withdrawal evaluated just
before the final morphine dose was manifested as teeth
chattering, ptosis, wet dog shakes, urination, cheek tremors,
freezing, eye blinking, and sniffing in rats and freezing,
diarrhea, tremors, eye blinking, and ptosis in mice. The
variety of withdrawal signs appears to be similar to those
observed in chronic morphine use in rodents. Male and
female rats treated intermittently with increasing doses
of morphine displayed higher global withdrawal scores at
the end of the 14-h and 24-h dosing intervals, respectively
(Figures 1 and 2). Intermittent morphine treatment also
produced higher global withdrawal scores in male mice
at the end of the 12-h and 17-h dosing intervals (Figure
3). These results support the suggestion that intermittent
injections of morphine allow withdrawal during dosing
intervals (18). The withdrawal symptoms observed in both
species are obviously less pronounced than those reported
in previous studies. This indicates that partial withdrawal is
associated with intermittent morphine administration. The
severity of the withdrawal score between male and female
rats is inconsequential. This finding is not in agreement with
the finding that male rats have more severe spontaneous
withdrawal syndrome than females (7). In contrast to
rats, mice showed sex-related differences in withdrawal
scores in both treatment regimens. These results contradict
previous observations that M-10/50 and M-20/100
morphine regimens allow spontaneous withdrawal in both
sexes (8). This discrepancy between the two studies may be
due to the differences in testing times (just before the last
dose vs. several hours after the last dose) and/or test session
durations (10 min vs. 30 min).
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Several withdrawal signs have been observed following
naloxone challenge in morphine-dependent animals
(5,6,11,16,30,31). Weight loss and jumping are considered
predominant signs for quantification of naloxone
withdrawal in both rats (33,34) and mice (6,11,35).
Accordingly, naloxone precipitated withdrawal weight
loss and jumping in morphine-treated male and female
rats (Figures 1 and 2). Both M-10/50 and M-20/100 male
mice also displayed significant weight loss and jumping,
and M-20-100 female mice exhibited significant jumping
following naloxone administration (Figure 3). There were
no sex-related differences in the expression of naloxoneprecipitated withdrawal signs in rats. In contrast, M-10/50
female mice did not show withdrawal signs, and M-20/100
female mice had less severe withdrawal (only jumping)
in respect to M-20/100 males. Studies on sex-related
differences in the expression of morphine withdrawal
syndrome precipitated by naloxone have produced
inconsistent results both in rats (4,7) and in mice
(5,6,11,35). Our results agree with the previous finding
showing that naloxone-precipitated withdrawal syndrome
is similar in male and female rats (7). Moreover, data
obtained from mice support the previous findings that
female mice are less prone to developing signs of naloxone
withdrawal syndrome than male animals (5,35).
Noradrenergic neurons from the locus coeruleus
are thought to be an essential component of opiate
withdrawal (36). Clonidine has been shown to alleviate
most of the somatic signs of opiate withdrawal with its
ability to reduce firing of these neurons via presynaptic
stimulation of α2-adrenoceptors (3,36). Acute or repeated
clonidine administration before (25,26,32,37,38) or after
(28,36,39) the cessation of morphine treatment effectively
decreases both spontaneous and naloxone-precipitated
withdrawal symptoms. Accordingly, in the present study,
self-administration of clonidine in the drinking water
for 4 days during the dosing interval attenuated the
spontaneous withdrawal associated with intermittent
morphine treatment in rats. Reduced water consumption
in the clonidine groups suggests achievement of adequate
amounts of clonidine, as the drug was shown to elicit
marked reduction in water intake (23,40). It has been
hypothesized that clonidine coadministration during longterm morphine treatment might diminish noradrenergic
hyperactivity and consequently the development of
dependence and withdrawal signs (37). Distinct from
the spontaneous withdrawal, the severity of naloxoneprecipitated weight loss and jumping did not differ between
morphine and clonidine + morphine groups. This finding
implies that clonidine self-administration during dosing
interval could not affect the development of dependence
on morphine. Repeated coadministration of clonidine
with morphine has been shown to either decrease (38)
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or potentiate (37) naloxone-precipitated withdrawal
symptoms. Neither of these contradictory findings was
supported by this study.
Considered a response to stress, novelty-induced
grooming has long been studied in neurobehavioral stress
research in mice and rats (41,42). Stress-evoked alterations
in grooming activity were reported with dramatic
increases in its frequency and duration (43,44). It has been
shown that withdrawal syndrome in morphine-dependent
rats is combined with the development of stress, reflected
by increased duration of grooming behavior (45,46).
Our results, however, do not imply a “stress-like” state
associated with spontaneous withdrawal syndrome in
animals treated intermittently with morphine (18). We
found that neither the duration (Figures 1 and 2) nor
the frequency (Figure 3) of grooming activity increases
in the novel environment in morphine-treated male and
female rats and mice. Instead, rats had reduced grooming
duration at the end of the 14-h dosing interval (Figure 1),
and both M-20/100 male and female mice had reduced
grooming frequency at the end of the 7-h dosing interval
(Figure 3). These results suggested sufficient blood
morphine levels after dosing intervals to affect grooming,
since grooming decreases in the first week of a repeated
morphine treatment regimen after animals receive daily
morphine injections (47). On the other hand, it has been
shown that injection of clonidine into the brains of rats
decreases grooming duration (48). Its administration in
drinking water, however, could not produce a similar effect
(Figure 1). Interestingly, grooming duration did not differ
between the morphine + clonidine and control groups.
Since clonidine has a sedative effect (48), this finding

might suggest an antistress activity during dose intervals.
Further experimentation using a detailed analysis of
grooming behavior, such as its ‘qualitative’ or patterning
characteristics (49,50), or other measures of anxiety, such
as elevated plus-maze behavior (51), may provide a better
assessment of stress and antistress effects associated with
the intermittent morphine treatment regimen.
In conclusion, intermittent injections of increasing
doses of morphine produce manifestations of spontaneous
withdrawal at the end of the dosing interval in rats and
mice, attenuated by administration of clonidine during
dose intervals. Novelty-induced grooming behavior in
the animals, however, could not reflect a withdrawalinduced stress associated with the treatment regimens.
Absence of significant spontaneous withdrawal signs
and presence of somewhat less pronounced naloxoneprecipitated withdrawal signs in female mice appear as
sex- and species-related differences in the development
of physical dependence on morphine. On the other
hand, opiate withdrawal syndrome powerfully motivates
drug-seeking and abuse in humans (2). Therefore,
spontaneous withdrawal associated with intermittent
morphine treatment in animals needs further evaluation
for its possible role in maintaining continued drug use and
response to drugs possessing sedative activity.
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